Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
SUN PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUN PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
SUN PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,072 | 320 | - | |
Low | Rs | 790 | 231 | - | |
Sales per share (Unadj.) | Rs | 182.9 | 95.3 | - | |
Earnings per share (Unadj.) | Rs | 35.7 | -24.0 | - | |
Cash flow per share (Unadj.) | Rs | 46.2 | -19.9 | - | |
Dividends per share (Unadj.) | Rs | 11.50 | 0 | - | |
Avg Dividend yield | % | 1.2 | 0 | - | |
Book value per share (Unadj.) | Rs | 233.4 | 74.8 | - | |
Shares outstanding (eoy) | m | 2,399.34 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.1 | 2.9 | 175.9% | |
Avg P/E ratio | x | 26.1 | -11.5 | -227.2% | |
P/CF ratio (eoy) | x | 20.1 | -13.9 | -145.3% | |
Price / Book Value ratio | x | 4.0 | 3.7 | 108.2% | |
Dividend payout | % | 32.2 | 0 | - | |
Avg Mkt Cap | Rs m | 2,233,361 | 46,551 | 4,797.7% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 82,960 | 2,922 | 2,839.5% | |
Avg. sales/employee | Rs Th | 0 | 3,747.7 | - | |
Avg. wages/employee | Rs Th | 0 | 680.6 | - | |
Avg. net profit/employee | Rs Th | 0 | -944.3 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 438,857 | 16,089 | 2,727.7% | |
Other income | Rs m | 8,199 | 113 | 7,276.8% | |
Total revenues | Rs m | 447,055 | 16,201 | 2,759.4% | |
Gross profit | Rs m | 112,900 | -2,788 | -4,049.4% | |
Depreciation | Rs m | 25,294 | 694 | 3,642.7% | |
Interest | Rs m | 1,720 | 436 | 394.7% | |
Profit before tax | Rs m | 94,084 | -3,806 | -2,472.2% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 8,476 | 238 | 3,564.4% | |
Profit after tax | Rs m | 85,608 | -4,054 | -2,111.7% | |
Gross profit margin | % | 25.7 | -17.3 | -148.5% | |
Effective tax rate | % | 9.0 | -6.2 | -144.2% | |
Net profit margin | % | 19.5 | -25.2 | -77.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 398,619 | 11,784 | 3,382.8% | |
Current liabilities | Rs m | 199,064 | 6,630 | 3,002.5% | |
Net working cap to sales | % | 45.5 | 32.0 | 142.0% | |
Current ratio | x | 2.0 | 1.8 | 112.7% | |
Inventory Days | Days | 147 | 111 | 132.6% | |
Debtors Days | Days | 95 | 124 | 76.8% | |
Net fixed assets | Rs m | 376,960 | 6,869 | 5,488.1% | |
Share capital | Rs m | 2,399 | 75 | 3,212.0% | |
Net worth | Rs m | 559,954 | 12,628 | 4,434.2% | |
Long term debt | Rs m | 0 | 4,438 | 0.0% | |
Total assets | Rs m | 775,794 | 23,855 | 3,252.1% | |
Interest coverage | x | 55.7 | -7.7 | -720.4% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.7 | 83.9% | |
Return on assets | % | 11.3 | -15.2 | -74.2% | |
Return on equity | % | 15.3 | -32.1 | -47.6% | |
Return on capital | % | 17.1 | -19.8 | -86.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 49,593 | 1,373 | 3,611.3% | |
From Investments | Rs m | -79,437 | -422 | 18,838.7% | |
From Financial Activity | Rs m | 23,761 | 4,028 | 590.0% | |
Net Cashflow | Rs m | 1,155 | 4,979 | 23.2% |
Compare SUN PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare SUN PHARMA With: ALBERT DAVID SUVEN PHARMACEUTICALS PIRAMAL PHARMA SEQUENT SCIENTIFIC BIOFIL CHEMICALS
On Monday, Indian share markets reversed the trend as the session progressed and ended the day higher.